美国 · SEC FORM 4
Moleculin Biotech, Inc.
MBRX · Nasdaq · CIK 0001659617 · Healthcare · Biotechnology
内部人信号
3 qualifying P purchase groups
当前 180 天评分窗口
19 同一窗口内观察到的 Form 4 交易行
0 sales · 16 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: CEO and President, Chief Financial Officer, Chief Science Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-08-03 · Foster Jonathan P..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 204,583
- 上期报告
- 287,608
- 日均成交量
- 1,712,392
- 回补天数
- ≤ 1.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | PICKER DONALD H | 买入 (P) | Common Stock | 173,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-03 | KLEMP WALTER V | 买入 (P) | Common Stock | 533,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-03 | Foster Jonathan P. | 买入 (P) | Common Stock | 293,333 | USD — | USD — | SEC 申报 ↗ |
| 2025-06-23 | KLEMP WALTER V | 买入 (P) | Common Stock | 675,675 | USD 0.37 | USD 250,000 | SEC 申报 ↗ |
| 2025-06-23 | Foster Jonathan P. | 买入 (P) | Common Stock | 270,270 | USD 0.37 | USD 100,000 | SEC 申报 ↗ |
| 2023-12-26 | KLEMP WALTER V | 买入 (P) | Common Stock | 188,404 | USD 0.69 | USD 129,999 | SEC 申报 ↗ |
| 2023-12-26 | George Robert E. | 买入 (P) | Common Stock | 14,493 | USD 0.69 | USD 10,000 | SEC 申报 ↗ |
| 2023-12-26 | Foster Jonathan P. | 买入 (P) | Common Stock | 28,986 | USD 0.69 | USD 20,000 | SEC 申报 ↗ |
| 2022-11-25 | KLEMP WALTER V | 买入 (P) | Common Stock | 45,000 | USD 1.28 | USD 57,600 | SEC 申报 ↗ |
| 2022-11-21 | KLEMP WALTER V | 买入 (P) | Common Stock | 22,500 | USD 1.15 | USD 25,875 | SEC 申报 ↗ |
| 2022-11-17 | KLEMP WALTER V | 买入 (P) | Common Stock | 24,742 | USD 1.02 | USD 25,237 | SEC 申报 ↗ |
| 2022-11-16 | KLEMP WALTER V | 买入 (P) | Common Stock | 85,213 | USD 0.97 | USD 82,657 | SEC 申报 ↗ |
Form 4 申报证据
25 transaction lines in the latest 365-day window; 100 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | KLEMP WALTER V | 期权行权/转换 (M) | Common Stock | 207,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-10-15 | KLEMP WALTER V | 代扣税 (F) | Common Stock | 48,659 | USD 0.37 | USD 18,009 | SEC 申报 ↗ |
| 2026-10-15 | Foster Jonathan P. | 期权行权/转换 (M) | Common Stock | 130,000 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (24 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | KLEMP WALTER V | 期权行权/转换 (M) | Common Stock | 207,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-10-15 | KLEMP WALTER V | 代扣税 (F) | Common Stock | 48,659 | USD 0.37 | USD 18,009 | SEC 申报 ↗ |
| 2026-10-15 | Foster Jonathan P. | 期权行权/转换 (M) | Common Stock | 130,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-10-15 | Foster Jonathan P. | 代扣税 (F) | Common Stock | 30,485 | USD 0.37 | USD 11,282 | SEC 申报 ↗ |
| 2026-08-03 | PICKER DONALD H | 买入 (P) | Common Stock | 173,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-03 | KLEMP WALTER V | 买入 (P) | Common Stock | 533,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-03 | Foster Jonathan P. | 买入 (P) | Common Stock | 293,333 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-22 | PICKER DONALD H | 期权行权/转换 (M) | Common Stock | 71 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-22 | PICKER DONALD H | 代扣税 (F) | Common Stock | 21 | USD 3.12 | USD 66 | SEC 申报 ↗ |
| 2026-06-22 | KLEMP WALTER V | 期权行权/转换 (M) | Common Stock | 360 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-22 | KLEMP WALTER V | 代扣税 (F) | Common Stock | 88 | USD 3.12 | USD 275 | SEC 申报 ↗ |
| 2026-06-22 | Foster Jonathan P. | 期权行权/转换 (M) | Common Stock | 174 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-22 | Foster Jonathan P. | 代扣税 (F) | Common Stock | 41 | USD 3.12 | USD 128 | SEC 申报 ↗ |
| 2026-06-20 | PICKER DONALD H | 期权行权/转换 (M) | Common Stock | 44 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | PICKER DONALD H | 代扣税 (F) | Common Stock | 13 | USD 2.88 | USD 37 | SEC 申报 ↗ |
| 2026-06-20 | KLEMP WALTER V | 期权行权/转换 (M) | Common Stock | 150 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | KLEMP WALTER V | 代扣税 (F) | Common Stock | 37 | USD 2.88 | USD 107 | SEC 申报 ↗ |
| 2026-06-20 | Foster Jonathan P. | 期权行权/转换 (M) | Common Stock | 109 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-20 | Foster Jonathan P. | 代扣税 (F) | Common Stock | 31 | USD 2.88 | USD 89 | SEC 申报 ↗ |
| 2025-11-04 | PICKER DONALD H | 期权行权/转换 (M) | Common Stock | 8,750 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-04 | PICKER DONALD H | 代扣税 (F) | Common Stock | 2,131 | USD 0.50 | USD 1,066 | SEC 申报 ↗ |
| 2025-11-04 | KLEMP WALTER V | 期权行权/转换 (M) | Common Stock | 28,750 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-04 | KLEMP WALTER V | 代扣税 (F) | Common Stock | 7,001 | USD 0.50 | USD 3,500 | SEC 申报 ↗ |
| 2025-11-04 | Foster Jonathan P. | 期权行权/转换 (M) | Common Stock | 25,648 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MBRX |
| CIK | 0001659617 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 100 transaction lines from 2020-07-13 to 2026-10-15 12 P purchase lines · 0 S sale lines · 88 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.